Heterocyclic compounds having hypolipidemic,...

Details Heterocyclic compounds having hypolipidemic,... Heterocyclic compounds having hypolipidemic,...

2006-05-09

2006-05-09

Richter, Johann (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07041837

ABSTRACT:
Novel β-aryl-α-substituted propanoic acids having hypolipidemic and hypocholesteremic activities.

REFERENCES:
patent: 5089514 (1992-02-01), Hulin
patent: 5306726 (1994-04-01), Hulin
patent: 5861173 (1999-01-01), Nishioka et al.
patent: 5885997 (1999-03-01), Lohray et al.
patent: 5889025 (1999-03-01), Lohray et al.
patent: 5889032 (1999-03-01), Lohray et al.
patent: 5985884 (1999-11-01), Lohray et al.
patent: 6048883 (2000-04-01), Haigh et al.
patent: 6054453 (2000-04-01), Lohray et al.
patent: 6130214 (2000-10-01), Lohray et al.
patent: 6159966 (2000-12-01), Lohray et al.
patent: 6166049 (2000-12-01), Smith
patent: 6265401 (2001-07-01), Lohray et al.
patent: 6294586 (2001-09-01), Yelle et al.
patent: 6313113 (2001-11-01), Lohray et al.
patent: 6362360 (2002-03-01), Andersson et al.
patent: 6369067 (2002-04-01), Gurram et al.
patent: 6440961 (2002-08-01), Lohray et al.
patent: 6444816 (2002-09-01), Das et al.
patent: 6521622 (2003-02-01), Ricks et al.
patent: 6525083 (2003-02-01), Acton, III et al.
patent: 6569901 (2003-05-01), Mogensen et al.
patent: 6573628 (2003-06-01), Sloupensky et al.
patent: 6589969 (2003-07-01), Tajima et al.
patent: 6602901 (2003-08-01), Jeppesen et al.
patent: 0753 298 (1997-01-01), None
patent: 90 3343 (1999-03-01), None
patent: WO 91/19702 (1991-12-01), None
patent: WO 94/01420 (1994-01-01), None
patent: WO 94/13650 (1994-06-01), None
patent: WO 94/29302 (1994-12-01), None
patent: WO 95/03038 (1995-02-01), None
patent: WO 95/17394 (1995-06-01), None
patent: WO 96/04260 (1996-02-01), None
patent: WO 96/04261 (1996-02-01), None
patent: WO 96/33998 (1996-10-01), None
patent: WO 97/25042 (1997-07-01), None
patent: WO 97/31970 (1997-09-01), None
patent: WO 97/36579 (1997-10-01), None
patent: WO 98/02159 (1998-01-01), None
patent: WO 98/28534 (1998-07-01), None
patent: WO 99/08501 (1999-02-01), None
patent: WO 99/16758 (1999-04-01), None
patent: WO 99/19313 (1999-04-01), None
patent: WO 99/20614 (1999-04-01), None
patent: WO 99/38850 (1999-08-01), None
patent: WO 00/23417 (2000-04-01), None
patent: WO 00/23445 (2000-04-01), None
patent: WO 00/23451 (2000-04-01), None
patent: WO 01/53257 (2001-07-01), None
A. N. Collins, G. N. Sheldrake and J. Crosby, in “Chirality in Industry II”, John Wiley & Sons, Inc., 1997, 81-98 and references therein.
Cancer Research, 58, 3344-3352 (1998).
Carcinogenesis, vol. 19 No. 11, 1949-1953 (1998).
Cell, 87, 377-389 (1996).
Cell, 55, 932-943 (1999).
Cell, 79, 1147-1156 (1994).
Cell, 83, 803-812 (1995).
Cell, 99, 239-242 (1999).
Cell Biology, 95, 14751-14756 (1998).
Current Biol., 5, 618-621 (1995).
E. L. Eliel and S. H. Wilen, in “Stereochemistry of Organic Compound”, John Wiley & Sons, Inc., 1994, 297-464 and references therein.
Endocrine Reviews, 20(5), 649-688 (1999).
Endocrinology 135, 798-800 (1994).
Exp. Clin. Endocrinol. Diabetes: 109(4), S548-559 (2001).
T. W. Greene and P. G. M. Wuts “Protective Groups in Organic Synthesis”, John Wiley & Sons, Inc., 1999, 3rdEd., 201-245 along with references therein.
J. Clin. Invest., 85, 962-967, 1990.
J. Medicinal Chemistry, 43(4), 527-550 (2000).
Jaques et al. “Enantiomers, Racemates and Resolution”, Wiley Interscience, 1981.
Knorr, L., Ber., 1885, 18, 299-311.
Macikinnon et al., J. Biol. Chem. 261, 2548-2552 (1986).
Med. Res. Rev., 20(5), 350-366 (2000).
Miller et al., Br. Med. J. 282, 1741-1744 (1981).
Molecular Cell, 465-470 (1998).
Nature Reviews: Drug Discovery: 1(4), 276-86 (2002).
Nature, 405, 421-424 (2000).
Paal C. Ber., 1885, 18, 367-371.
Petit D., Bonnefis M. T., Rey C. and Infante R., Effects of ciprofibrate on liver lipids and lipoprotein synthesis in normal and hyperlipidemic rats, Atherosclerosis, 74, 215-225 (1988).
Picardo et al., Arteriosclerosis, 6, 434-441 (1986).
Principles of Asymmetric Synthesis J E Baldwin Ed. Tetrahedron series, vol. 14, p. No. 311-316.
Proc. Natl. Acad. Sci. 93, 5793-5796 (1996).
Proc. Natl. Acad. Sci., 94, 237-241 (1997).
Remington: the Science and Practice of Pharmacy, 19thEd., 1995.
Ross and Glomset, New Engl. J. Med., 295, 369-377 (1976).
Science, 269, 543-46 (1995).
R. A. Sheldon, in “Chirotechnology”, Marcel Dekker, Inc. NY, Basel, 1993, 173-204 and references therein.
Stampfer et al., N. Eng. J. Med., 325, 373-381 (1991).
Trends Endocrine. Metabolism, 4, 291-296 (1993).
Trends in Pharmacological Sci., 469-473 (2000).
Trinder, P. Ann. Clin. Biochem. 1969. 6: 24-27.
Wieland, O. Methods of Enzymatic Analysis. Bergermeyer, H., O., Ed., 1963. 211-214.
DDT, vol. 6, No. 13, 2001, p. 654-55, “Unravelling metabolic syndrome X.”
Diabetes Mellitus—A Fundamental Text book, pp. 326-329,611-613, “Definition and Classification of Diabetes Mellitus and the New Criteria for Diagnosis.”
Am Heart J.Dec. 1988; 116(6 Pt 2): 1713-24, “The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease.”
3rdReport of the National Cholesterol Education Program (NCEP), Expert Panel on ‘Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)’—NIH, USA.
Diabetes Mellitus—A Fundamental Text book, pp. 326-329, 611-613, “Fatty Acids and Insulin Resistance.”
Ann NY Acad Sci.Nov. 18, 1999; 892:25-44, “Etiology of the metabolic syndrome : potential role of insulin resistance, leptin resistance, and other players.”
Horm Metab Res.Feb. 2003; 35(2); 92-96, “Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion.”
Metabolism. Jun. 2003; 52(6):713-9, “Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome.”
The Journal of Clinical Endocrinology & Metabolism 2003, 88(5):2031-2036, “Glucose Intolerance, Insulin Resistance, and Hyperandrogenemia in First Degree Relatives of Women with Polycystic Ovary Syndrome.”
Diabetes Care. Jun. 2003; 26(6): 1752-8, “Type 2 Diabetes and Subsequent Incidence of Breast Cancer in the Nurses' Health Study.”
Exp Biol Med (Maywood). Apr. 2003; 228(4): 396-405, “Insulin resistance and its contribution to colon carcinogenesis.”
Cancer Epidemiology, Biomarkers & Prevention. Dec. 2000; 9:1271-79. “Possible Mechanisms Relating Diet and Risk of Colon Cancer.”
Pol Arch Med Wewn. Aug. 1998; 100(2):125-32, “Bone density in type 2 diabetes as related to obesity and adrenal f unction.”
FEBS Lett. Apr. 7, 2000;471(1):119-24, “Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts.”
Endocrinology1999; 140(11): 5060-65, “Thiazolidinediones inhibit osteoclast-like cell formation and bone absorption in vitro.”
Am J Surg. Jan. 1995; 169(1): 105-9, “Alterations in hepatocyte insulin binding in chronic pancreatitis : effects of pancreatic polypeptide.”
J Clin. Endocrinol. Metab. May 2001; 86(5): 2289-95, “Dyslipidemia in familial partial lipodystrophy caused by an R482W mutation in the LMNA gene.”
Clin Nephrol. Nov. 2000; 54(5): 366-73, “Mild renal dysfunction is associated with insulin resistance in chronic glomerulonephritis.”
J Am Soc Nephrol. Jul. 2002; 13(7): 1894-900, “Insulin Resistance as an Independent Predictor of Cardiovascular Mortality in Patients with End-Stage Renal Disease.”
Kidney Int. Sep. 2002; 62(3): 963-70, “Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study.”
Aliment Pharmacol Ther. Feb. 1999; 13(2): 209-17, “Glucose metabolism and insulin sensitivity in inactive inflammatory bowel disease.”
J Am Acad Dermatol. Jul. 1985; 13(1): 1-30, “Xanthomas and hyperli

Affiliated with

Also associated with

Rating

Heterocyclic compounds having hypolipidemic,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic compounds having hypolipidemic,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds having hypolipidemic,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3596390